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Abstract
Pharmacological tools—‘chemical probes’—that intervene in cell signaling cascades are
important for complementing genetically-based experimental approaches. Probe develop-
ment frequently begins with a high-throughput screen (HTS) of a chemical library. Herein,
we describe the design, validation, and implementation of the first HTS-compatible strategy
against any inositol phosphate kinase. Our target enzyme, PPIP5K, synthesizes ‘high-
energy’ inositol pyrophosphates (PP-InsPs), which regulate cell function at the interface
between cellular energy metabolism and signal transduction. We optimized a time-
resolved, fluorescence resonance energy transfer ADP-assay to record PPIP5K-catalyzed,
ATP-driven phosphorylation of 5-InsP7 to 1,5-InsP8 in 384-well format (Z’ = 0.82 ± 0.06).
We screened a library of 4745 compounds, all anticipated to be membrane-permeant,
which are known—or conjectured based on their structures—to target the nucleotide bind-
ing site of protein kinases. At a screening concentration of 13 μM, fifteen compounds inhib-
ited PPIP5K >50%. The potency of nine of these hits was confirmed by dose-response
analyses. Three of these molecules were selected from different structural clusters for anal-
ysis of binding to PPIP5K, using isothermal calorimetry. Acceptable thermograms were
obtained for two compounds, UNC10112646 (Kd = 7.30 ± 0.03 μM) and UNC10225498
(Kd = 1.37 ± 0.03 μM). These Kd values lie within the 1–10 μM range generally recognized
as suitable for further probe development. In silico docking data rationalizes the difference
in affinities. HPLC analysis confirmed that UNC10225498 and UNC10112646 directly
inhibit PPIP5K-catalyzed phosphorylation of 5-InsP7 to 1,5-InsP8; kinetic experiments
showed inhibition to be competitive with ATP. No other biological activity has previously
been ascribed to either UNC10225498 or UNC10112646; moreover, at 10 μM, neither
compound inhibits IP6K2, a structurally-unrelated PP-InsP kinase. Our screening strategy
may be generally applicable to inhibitor discovery campaigns for other inositol phosphate
kinases.
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Introduction
Inositol phosphate kinases (IP3K, IPMK, ITPK1, IP5K, IP6K and PPIP5K) perform numerous
biological processes through their participation in a carefully-regulated,metabolic network
that converts phospholipase C-derived Ins(1,4,5)P3 into an array of more highly phosphory-
lated cell-signalingmolecules [1–3]. Among these metabolites, considerable attention is cur-
rently being focused upon the inositol pyrophosphates (PP-InsPs), the distinguishing feature
of which is the possession of ‘high-energy’ diphosphate groups at the 1- and/or 5-positions of
the six carbons that comprise the inositol ring [3,4]. Multiple and diverse cellular activities
have been attributed to the PP-InsPs, but an over-arching hypothesis views them as acting as
an interface between energymetabolism and cell-signaling [3,5,6]. Our laboratory has a partic-
ular interest in the IP6Ks and PPIP5Ks that synthesize PP-InsPs [7,8]. Human PPIP5K has
been the focus of the current study; this enzyme catalyzes the ATP-dependent phosphorylation
of 5-InsP7 to 1,5-InsP8.
To date, research into the biology of inositol phosphate kinases has been well-servedby
genetic studies, including gene knock-outs in both organisms and cultured cells. However,
interpretations of the resulting phenotypes can be complicated by non-enzymatic scaffolding
roles for the targeted protein, as well as indirect consequences of secondary genetic changes
[9]. One observation that is particularly illustrative is the altered degree of transcription of over
900 genes (2-fold change in expression), following the deletion of vip1 (a PPIP5K homo-
logue) in Saccharomyces cerevisiae. [10]. Thus, selective, cell permeant inhibitors of a particular
inositol phosphate kinase—‘chemical probes’ [11]—have been recognized to have experimental
utility for complimenting genetic approaches [12]. Indeed, the benefits to basic research accru-
ing from the generation of small-molecule chemical probes has been the main purpose of the
NIHMolecular Libraries Initiative [13]. Beyond that, there is the prospect that such probes can
seed the development of drugs that may improve human health [14]. For example, it has been
suggested that a PPIP5K inhibitor could offer a novel strategy for treating diabetes, inflamma-
tion and cancer [4].
Very little attention has previously been directed toward developing inositol phosphate
kinase inhibitors. Arguably the most advanced study was that which identifiedN2-(m-(tri-
fluoromethyl)benzyl)N6-(p-nitrobenzyl)purine (TNP) as an IP3K inhibitor [15]. This discov-
ery emerged after the enzyme was manually screened against a library of 275 compounds
generated by introducing structural variations at the 2-, 6-, and 9-positions of the purine ring
[16]. In later work [12], TNP was repurposed as a potentially useful inhibitor of the IP6Ks,
although some reservations concerning target specificity go beyond the reagent’s ability to also
block IP3K activity [4]. Other than TNP, we are not aware of any commercial or academic
sources for any other validated, cell-permeant inhibitor that can specifically target a particular
inositol phosphate kinase.
The IP3K assays used in the discovery of TNP were performed using tedious, manual sepa-
ration of radiolabeled inositol phosphate substrates and products by ion-exchange chromatog-
raphy [12,15]. Such methodology cannot be adapted to an automated, high-throughput format
which would provide a much more efficient approach to screen for inhibitors among large
compound libraries [17]. Indeed, to date there has not been a published description of a high-
throughput screen (HTS) against any member of the inositol phosphate kinase signaling fam-
ily. Undertaking HTS in such circumstances can be a daunting task; the highest failure rates
during screening—i.e., the absence of useful ‘hits’—have been associated with the target being a
member of a group of proteins that have not previously been interrogated by HTS [17–19]. For
example, millions of chemicals are available for screening; testing such huge numbers can be
technically and financially prohibitive, especially for an academic laboratory. To ameliorate
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this problem, interest has grown in rendering screeningmore efficient, by the curation and
application of smaller, focused libraries that target protein families with functionally or chemi-
cally related binding sites [17]. Such libraries are also considered to be more efficient at identi-
fying drug-like and lead-likemolecules for further optimization [17,20]. Given the limited
precedent, selection of a suitable library to screen a new class of target, such as an inositol phos-
phate kinase, is a critical aspect of the entire HTS strategy.
Our choice of a library was influenced by the recognition that the substrate binding pockets
of inositol phosphate kinases are all highly electropositive [7,8,21,22]. Such ligand-binding
sites would be expected only to be effectively occupied by polar molecules that do not readily
cross cell membranes, thus potentially deeming inositol phosphate binding pockets to be
undruggable [23]. For the current study we posited that the more hydrophobic nucleotide-
binding site of an inositol phosphate kinase would offer a potentially more tractable target
[23].
With the nucleotide-binding sites of protein kinases specifically in mind as drug-targets, a
number of chemical libraries have been curated that comprise compounds either known—or
predicted in silico—to inhibit catalytic activity. In the current study we have investigated
whether such a librarymight be productive for targeting the nucleotide binding site of PPIP5K.
This approach was pragmatic, although rather speculative, since PPIP5Ks are only distantly
related to protein kinases, and the two classes of enzymes do not exhibit significant primary
sequence homology [24,25]. The particular 4,745-member (‘5K’) protein-kinase focused library
that we selected has been describedpreviously [26,27]. All of its molecules are anticipated to be
membrane permeant. Our goal, mirroring that of the NIHMolecular Libraries Initiative [13],
was to identify ‘pre-probes’ [11] as the basis for subsequent modification to yield chemical
probes with appropriate potency and selectivity.
Full length PPIP5Ks are not easily amenable to designing a robust assay for screening cam-
paigns, as they are large (140–160 kDa) proteins that are difficult to express and purify in suffi-
cient quantities. Fortunately, the kinase activities are self-contained in the N-terminally-
located catalytic domain [25,28,29], which can be readily expressed in Escherichia coli and then
purified to homogeneity [8]. To develop an assay suitable for screening, we have adapted
recently introducedmethodology that utilizes homogenous time-resolved fluorescence reso-
nance energy transfer (HTRF) in an antibody-based assay to record ADP formation from ATP
[30]. In our current study, we describe how this HTS assay for PPIP5K was optimized, vali-
dated, and deployed. Finally, since we have previously solved the crystal structure of this kinase
domain with ATP bound [8], we docked two confirmed ‘hits’ into the enzyme’s nucleotide
binding site in silico, thereby deriving ‘proof-of-principle’ that these molecules can seed future
improvements in inhibitor efficacy. Moreover, we propose the procedures that we have devel-
oped should be applicable to the other members of the inositol kinase family.
Materials and Methods
Reagents and Consumables
The Adapta Universal Kinase Assay Kit was purchased from Thermo Fisher Scientific (Pitts-
burg, PA, USA). The ATP, ADP, and EDTA that were used in these assays were provided with
the Adapta kit; these reagents were also used in HPLC assays. The 384-well white solid-bottom
plates used for HTS were purchased from Greiner Bio One (Monroe, NC, USA). The 5-InsP7
was synthesized as describedpreviously [31]. InsP6 was purchased from EMDMillipore. The
kinase-focused library of 4745 molecules is described in [26,27,32]; the PKIS (published kinase
inhibitor set) includes a total of 815 compounds in sets 1 and 2, as described in [33,34]. All
compounds in these libraries were dissolved in 100% DMSO. Solid stocks of UNC10225354
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(Sigma Aldrich), UNC10225498 (ChemDiv), and UNC10112646 (Sigma Aldrich) were pur-
chased for use in dose-response, ITC, and HPLC experiments.
The GSK PKIS library has previously been prepared as 1 μl samples (10 mM in DMSO) in
384-well V-bottom polypropylene ‘daughter’ microplates (Greiner, Monroe, NC), sealed by a
ALPS 3000 microplate heat sealer (Thermo Fisher Scientific) and stored at −20°C.
The compound plates of the 5K kinase-focused library were prepared by resuspending the
powder stock to 10 mM in 100% DMSO in barcoded glass vials with sonication using a Covaris
S2 sonicator (Covaris,Woburn, MA). Next, 10 μl aliquots of these compounds were transferred
to 384-well V-bottom polypropylene ‘mother’ microplates that had been barcoded to ensure
the integrity of the catalog using a Tecan Genesis 200 (Münnedorf, Switzerland). Finally, a
Multimek was used to transfer 1 μl aliquots from the ‘mother’ plates to 384-well V-bottom
polypropylene ‘daughter’ microplates which were then heat sealed and stored at −20°C. Com-
pound libraries are the property of UNC.
Enzyme Preparation
The human PPIP5K2 kinase domain (residues 1–366), NCBI (National Center for Biotechnol-
ogy Information) accession number {"type":"entrez-protein","attrs":{"text":"NP_056031.2","ter-
m_id":"41281583","term_text":"NP_056031.2"}}NP_056031.2, the human PPIP5K1 kinase
domain (residues 1–376), NCBI accession number NP_001124330.1, and the human IP6K2
(residues 1–270), NCBI reference sequence XP_648490.2, were expressed in E. coli and purified
as previously described [7,8]. The proteins were stored at −80°C.
HTS Assay
On the day of use, the PKIS and 5K ‘daughter’ plates (1 μl of 10 mM in 100% DMSO (see
above)) were diluted in two steps. First, 49 μl of the Adapta kinase buffer A (50 mMHEPES,
pH 7.5, 10 mMMgCl2, 1 mM EGTA, 0.01% Brij-35) was added using a ScientificMultidrop
Combi Reagent Dispenser (ThermoFisher) to create 200 μM dilutions in 2% DMSO. These
dilution plates were then centrifuged for 2 minutes at 14,000 rpm. Next, 1 μl from the dilution
plates was dispensed into the wells of 384-well white solid bottom plates (Greiner BioOne)
using a Multimek (Nanoscreen) to give a final concentration of 13 μM in the 15 μl kinase reac-
tion. PPIP5K was added in 5 μl of buffer A plus 0.5% DMSO with a Multidrop (ThermoFisher)
to a final concentration of 600 nM. The final addition (using the Multidrop) to initiate the
kinase reactions was 9 μl of ATP and 5-InsP7 at final concentrations of 20 μM and 10 μM,
respectively, in kinase buffer A plus 0.5% DMSO. A concentration of 20 μM ATP was chosen
to match the Km value for this substrate. Plates were covered and incubated at 25°C for 1 hour.
The kinase assays were quenched with 5 μl of EDTA, Eu-anti-ADP antibody, and Alexa FluorR
647-labeled ADP tracer (the ‘ADP tracer’) at final concentrations of 15 mM, 6 nM and 5 nM,
respectively. The amount of ADP that accumulated was determined using an HTRF assay, pre-
optimized as follows: A titration of ADP tracer in the presence of ATP and Eu-anti-ADP anti-
body was performed as described in the vendor’s instructions; the optimum ADP tracer con-
centration was found to be 5nM. An ATP-ADP titration curvewas performed (as described in
the vendor’s instructions), using a total nucleotide concentration of 20 μM. This ATP-ADP titra-
tion curvewas used to determine the percent conversion of ATP to ADP in either the presence
or the absence of PPIP5K. Less than 20% of the ATP was consumed in these reactions, and the
reaction rates were linear with time throughout the course of these 60 minute incubations.
Plates were allowed to equilibrate for 30 min in the dark before reading HTRF signals on an
EnVision (Perkin Elmer) plate reader (excitation = 320 nm, emission = 665 nm and 615 nm).
The HTRF signal was calculated as a ratio of the signals from the 665 nm (acceptor) and 615
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nm (donor) channels. Percent inhibition was calculated by normalizing each of the compound
wells to the mean signals from the positive control wells containing UNC10225354 (100 μM
for HTS and 20 μM for dose-response).
ATP Competition
To determine the mechanism by which hits from the screen inhibited the kinase (competitive,
non-competitive or uncompetitive with respect to ATP), dose-response experiments were per-
formed using either 20 μM, 100 μM, or 500 μM ATP with ten, 2-fold serial dilutions of inhibi-
tor from 100 μM. Incubation times varied for each concentration of ATP to maintain
approximately 20% conversion of ATP to ADP. All other assay conditions were as described
above.
Isothermal Calorimetry
All ITC measurements were recorded at 25°C with an AutoITC200 microcalorimeter (Malvern
Instruments, UK). All protein and compound stock samples were prepared in the kinase buffer
A (50 mMHEPES, pH 7.5, 10 mMMgCl2, 1 mM EGTA, 0.01% Brij-35), and then diluted in
the same buffer to achieve the desired concentrations: 50 μM protein and 0.5 mM compound.
The concentration of the protein stock solution was established using the Edelhochmethod,
whereas compound stock solutions were prepared based on mass. A typical experiment
included a single 0.2 μl compound injection into a 200 μl cell filledwith protein, followed by 26
subsequent 1.5 μl injections of compound. Injections were performedwith a spacing of 180 sec-
onds and a reference power of 8 μcal/sec. Control experiments were performed by titrating
each compound into buffer under identical conditions to determine the heat signals, if any,
that arise from diluting the compound. If applicable, the heats of dilution generated were then
subtracted from the protein-compound binding curves. The initial data point was routinely
deleted. The titration data were analyzed using Origin Software (Malvern Instruments, UK) by
non-linear least squares, fitting the heats of binding as a function of the ligand: protein ratio to
a one site binding model.
Molecular Docking
Small-molecule structures were docked into the active site of PPIP5K2 (PDB: 3T54) [35] using
the Glide program [36] in standard docking precision mode (Glide SP). The binding region
was defined by a 20Å × 20Å × 20Å box centered on a reference ligand. A scaling factor of 0.8
was applied to the van derWaals radii. Default settings were used for all the remaining parame-
ters. The top 3 poses were generated for each ligand and subjected to energyminimization
using OPLS-2005 force field and visual inspection.
HPLC Assays
For HPLC analysis of PPIP5K activity, the assays contained kinase buffer A plus 20 μM ATP,
600 nM enzyme, 10 μM 5-[3H]InsP7 (approximately 5000 d.p.m), and either inhibitor (10 μM)
in 0.5% DMSO or vehicle alone, all in a final volume of 100 μl. Assays were run for 60 min at
25°C. For the IP6K assays, the reaction contained 1 mMATP (i.e., the Km value), 50 nM
enzyme, 10 μM [3H]InsP6 (approximately 5000 d.p.m), and either inhibitor (10 μM) in 0.5%
DMSO or vehicle alone, in a final volume of 100 μl in kinase buffer A with 1 mM additional
MgSO4. Assays were run for 15 min at 37°C.
Assays were acid quenched (by addition of 0.2 vol of 2 M perchloric acid plus 1 mg/ml
InsP6), neutralized (by addition of 68 μl 1M KCO3 plus 1mM EDTA), and chromatographed
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on a 4.6 × 125 mm Partisphere SAXHPLC using an ammonium phosphate gradient generated
from Buffer B (1 mMNa2EDTA) and Buffer C (Buffer B plus 1.3 M (NH4)2HPO4, pH 3.85
with phosphoric acid). The gradient (1 ml/min) is as follows: 0–5 min, 0% C; 5–10 min, C
increased linearly from 0 to 45%; 10–60 min, C increased linearly from 45 to 100%; 60–75 min,
C was 100%. From each run 1 ml fractions were collected, vigorously mixed with 4 ml Mono-
Flow 4 scintillant (National Diagnostics,Manville NJ), and counted using a liquid scintillation
counter.
Data Analysis
Data are presented as mean ± SEM of at least three biological replicates. Comparisons among
groups were made by two-tailed t test for repeated measurements using GraphPad Prism. Val-
ues of p<0.05 with a confidence interval of 95% were considered statistically significant.
Results and Discussion
Design of the High-Throughput PPIP5K Assay
It has previously been proposed that a ‘reverse-kinase’ assay of PPIP5K (ADP-dependent
dephosphorylation of 1,5-InsP8 to 5-InsP7) might be amenable to an HTS format [37]. This
was the approach that we initially attempted, using a luciferase-based assay for ATP produc-
tion (S1A and S1B Fig). However, the hit-rate was unacceptably high, in part due to many
false-positives (S1B Fig). Nevertheless, UNC10225354 was one genuine hit that did emerge
from the reverse kinase screen.We next developed an HTS compatible assay of ATP-driven
InsP8 production from 5-InsP7 by PPIP5K using UNC10225354 as a positive control. We opti-
mized a HTRF-based immunoassay for the detection of ADP (Fig 1).
In order to maximize the ability to detect inhibitors of nucleotide-binding by PPIP5K from
within the kinase-focused library, irrespective of their mechanism of inhibition (competitive,
non-competitive or uncompetitive), we used an ATP concentration that corresponded to its
Km value [38]. Our group had previously determined the Km of ATP to be 20 μM [37]. The
5-InsP7 concentration (10 μM) was selected so as to support measurable ATP consumption
(<20%) at near initial rates; assay trials determined this goal could be accomplished in 1 hour
assays performed at 25°C. An advantage of the HTRF assay is its sensitivity to the ADP formed
even by a low percentage of ATP metabolism [39]. The detailed assay protocol can be found in
the Materials and Methods and is summarized Table 1.
The HTS assay can be divided into three phases (Fig 1). First is the kinase reaction phase (1
hour at 25°C). Next, the reactions are quenched with EDTA, simultaneously with the addition
of a detection solution of Europium-labeled anti-ADP antibody, and an Alexa Fluor1 647
labeled ADP tracer. The ADP formed by the kinase reaction displaces the ADP tracer from the
antibody. The final phase is the HTRF readout, which is inversely proportional to the degree of
kinase activity (Fig 1). Thus, the higher the HTRF signal, the greater the degree of inhibition.
The HTRF ratiometric read-out limits fluctuations in signal variability caused by any well-to-
well variations in sample turbidity and reagent volumes.
DMSO Tolerance. 100% DMSO was used to dissolve all of the stock compounds in the
kinase-focused library and the PKIS libraries; the influence of the solvent upon the HTS assay
was investigated by titrating it into the kinase reaction at varying concentrations (S2 Fig). We
found that 0.5% DMSO was tolerated by the assay (<2% inhibition of PPIP5K activity). The
HTRF signal was found to be stable for at least 4 hours (S2 Fig). DMSO was therefore present
at a final concentration of 0.5% for all subsequent HTRF assays.
Assay Validation with the PKIS Library. HTSmolecule libraries are typically validated
for performance with a LOPAC library of 1280 pharmacologically active compounds, which
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include a limited number of known kinase inhibitors. For our study, we also wanted the valida-
tion library to interrogate proof-of-principle that a protein kinase focused library is appropriate
for an HTS of an inositol phosphate kinase.We therefore selected a kinase-focusedscreen for
the validation library: the GSK published kinase inhibitor set (PKIS) that includes 815 com-
pounds [33,34]. Compounds were screened at a single concentration of 13 μM in technical
duplicates performed on two successive days to give 4 total replicate measurements (Fig 2A
and 2B).
The Z0 factor is a statistical benchmark to assess the suitability of an assay for HTS [40] and
is a measure of the reproducibility in the difference in the dynamic range of the assay across a
large number of wells. An assay with ideal reproducibility displays a Z0 factor of 1; a Z0 factor
greater than 0.5 is considered acceptable for a good high-throughput assay [40,41]. The Z0 fac-
tor calculated for the PKIS screen is 0.78 ± 0.03 (Fig 2C), confirming that these assay condi-
tions are suitable for compound screening.
We used two additional criteria to judge the precision of the assay. First, we established the
percent coefficient of variation using a single dose (100 μM) of the inhibitor UNC10225354 as
a positive control. The value that we obtained (7.5 ± 1.6%, Fig 2D) is well below the generally
acceptable upper limit %CV20 [42]. These data are not reflected in the Z’ factor calculation
Fig 1. Schematic depicting the three phases of the HTS Assay for PPIP5K. The schematic describes how the degree of PPIP5K activity is inversely
proportional to the magnitude of the HTRF signal. During the kinase reaction 5-InsP7 phosphorylation to 1,5-InsP8 is coupled to ATP conversion to ADP.
After 60 minutes the kinase reactions are quenched with EDTA (not shown) and the ADP detection reagents are added. The HTRF signal is measured after
another 30 minutes. (A) In the absence of inhibitor there is production of ADP, which competes with the ADP tracer for the ADP antibody, resulting in a low
HTRF signal. (B) In the presence of inhibitor, ADP production is decreased thereby allowing ADP tracer to bind to the ADP antibody, resulting in a high
HTRF signal. The hypothetical examples shown in (A) and (B) represent two extreme assay outcomes of 100% and 0% phosphorylation respectively.
doi:10.1371/journal.pone.0164378.g001
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Table 1. Steps of the PPIP5K HTS Assay.
Step Parameter Value Description1
1 Library Compound Dilution 50 μl Stocks (Columns 3–22) in 100% DMSO diluted with kinase buffer A to 2% DMSO using a
Multidrop dispenser.
2 Library Compound Addition 1 μl Dilutions dispensed into assay plates using a Mutlimek instrument
3 Addition of either UNC10225354 Control
Compound or vehicle
1 μl Either 2% DMSO (Columns 1 and 24), or control 20 μM (5K) or 100 μM (PKIS); Column 2), and
2-fold dose-response dilution of control (Column 23) added using a Multidrop dispenser.
4 Enzyme Addition 5 μl PPIP5K and no enzyme solutions in kinase buffer A and 0.5% DMSO; reagent bottles are kept
on ice
5 Substrate and ATP Addition 9 μl 5-InsP7 and ATP master mix in kinase buffer A and 0.5% DMSO, reagent bottles are kept on
ice
6 Incubation time 60
min
25˚C
7 Kinase Reaction Quenched 5 μl EDTA, antibody, and ADP tracer master mix in kinase buffer A and 0.5% DMSO; reagent
bottles are protected from light
8 Incubation time 30
min
25˚C in the dark
9 HTRF Detection Envision plate reader; HTRF mode (excitation at 320 nM and emission at 615 nm and 665 nm)
1See Materials and Methods for more details and definitions
doi:10.1371/journal.pone.0164378.t001
Fig 2. Application of the PKIS library to judge performance of the HTS assay. (A) Representative technical replicates measured on the same day. (B)
Comparison of the mean values of biological replicates (black and white circles) obtained on two different days. R2 = 0.98. (C) Z’ Factor (0.78 ± 0.03) (D) %
CV (7.5 ± 1.6) (E) Signal:background ratio (15.8 ± 1.5) (F) These plates included negative controls (DMSO; gray circles, broken line and positive controls
(100 μM UNC10225354; gray square, broken line). Each plate also contained one 10-point titration for UNC10225354; data (black circles) depict means and
SEMs (n = 5). IC50 = 4.8 ± 0.3 μM. In these experiments, 100% activity is equivalent to consumption of 19.3 ± 1.1% of the ATP.
doi:10.1371/journal.pone.0164378.g002
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which uses a ‘no enzyme’ positive control and therefore must be determined separately. We
additionally judged assay precision from the low variability in the determined IC50 value for
the dose-response curve for UNC10225354 (4.8 ± 0.3 μM; Fig 2F). The robustness of the assay
can be judged by the high signal:background ratio (15.8 ± 1.5) which was well above the mini-
mum value of 5 that is generally acceptable (Fig 2E) [43]. UNC10225354 was also plated at a
single concentration of 100 μM in replicates to fully inhibit PPIP5K, and thereby provide a
maximumHTRF signal (Fig 1) to which the activities of library compounds screenedwere
normalized.
In addition to validating our HTS, our data indicate that 8 molecules from the PKIS library
inhibit PPIP5K activity>50%. These results confirm the value, in principle, of screening an
inositol phosphate kinase against a protein kinase-focused library. However, we did not have
access to sufficient stocks of the PKIS library to further pursue validation of these particular
hits.
Screen of the 5K Kinase-FocusedLibrary. We next performed an HTS with a kinase-
focused library of 4,745 (‘5K’) compounds compiled by the Center for Integrative Chemical
Biology and DrugDiscovery at UNC [26,27,32]. Again, there was good correlation between
technical (Fig 3A) and biological (Fig 3B) replicates. The Z’ factor was consistently high at an
average of 0.82 ± 0.06 across 19 plates (Fig 3C). The %CV (8.6 ±1.3) and the signal:background
ratio (16.4 ±1.1) both were consistent across plates and demonstrated an excellent dynamic
Fig 3. HTS of PPIP5K against a kinase-focused library of potential nucleotide antagonists. (A) Representative technical replicates measured on the
same day. (B) Comparison of the mean values of biological replicates (black and white circles) obtained on two different days. R2 = 0.99. (C) Z’ Factor
(0.82 ± 0.06) (D) %CV (8.6 ± 1.3) (E) Signal:background ratio (16.4 ± 1.1) (F) These plates included negative controls (0.5% DMSO; gray circle, broken line)
and positive controls (20 μM UNC10225354; gray square, broken line). Each plate also contained one 10-point titration for UNC10225354; data (black
circles) depict means and SEMs (n = 5). IC50 = 5.2 ± 0.2 μM. In these experiments, 100% activity is equivalent to consumption of 18.9 ± 1.5% of the ATP.
doi:10.1371/journal.pone.0164378.g003
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range (Fig 3D and 3E). Control compound UNC10225354 exhibited an IC50 of 5.2 ± 0.2 μM
for inhibition of PPIP5K activity (Fig 3F) which is consistent with its potency in the PKIS
library screen (Fig 2F).
PPIP5K was screened against each compound in the 5K kinase-focused library at a concen-
tration of 13 μM. Only 15 molecules, including the positive control UNC10225354, were con-
sidered as hits (i.e. kinase activity was inhibited>50%: Fig 3A). We propose that this low hit
rate (0.3%) reflects the ATP-binding site of PPIP5K2 having some structural differences from
the ATP-binding sites of the protein kinase family, which the 5K library was originally
designed to target. These hits fell into one of ten clusters based on structural similarity (S1
Table). This result indicates that our methodology generated structural diversity among hits.
It is notable that in a previous study in which the 5K library was used for its original pur-
pose–screening for inhibitors of a protein kinase, in this case TBK1 –the hit rate was 4.8%
(kinase activity inhibited>50% at 10 μM [26]). The 16-fold lower hit rate for the same library
screened against PPIP5K may, in part, reflect its lack of homology with protein kinases (see the
Introduction). On the other hand, among the 15 initial hits for PPIP5K, we are only aware of
one (UNC10225354) that has previously been reported to inhibit any other kinase (p38 MAPK
[44]). That information suggests the 5K librarymay have yielded leads with some specificity
for an inositol phosphate kinase.
Validation of 5K Hits by Dose-ResponseAnalysis. Among the 15 initial ‘hits’ from the
HTS (see above), 14 were available (either from stocks or commercial sources) for retesting in
triplicate in a 10-point dose–response assay to confirm activity and quantify potency. This retest-
ing led us to discard 5 of these hits because they did not demonstrate reproducible IC50 values
of less than 13 μM (S3 Fig). Next, 3 of the remaining hits which exhibited IC50 values<10 μM
(see [45,46]) were selected from different structural clusters (S1 Table): UNC10112646,
UNC10225498, and the positive control UNC10225354 (Fig 4A–4C). These hits were tested in
dose-response against the kinase domain of both isoforms of PPIP5K, i.e., PPIP5K1 and
PPIP5K2 (Fig 4D and S4 Fig). Each isoform showed similar sensitivities to each of the three
inhibitors (Fig 4D and S4 Fig). That is, the two IC50 values for each inhibitor were determine by a
paired two-tailed t-test to be within the same normal distribution (p value = 1). This outcome is
consistent with the strict conservation of nucleotide binding results in the two kinase domains
[8]. None of these three inhibitors showed activity in the counterscreen (Fig 4E), indicating that
they were not false-positives due to interference with the ADP detection reagents.
Characterization of Inhibitor-Enzyme Interactions by Isothermal
Calorimetry
Isothermal calorimetry (ITC) is considered the ‘gold standard’ for quantifying intermolecular
interactions in a label free manner [47]. In this study, we used ITC to investigate the interaction
between PPIP5K and the three inhibitors of particular interest noted above (Fig 5A–5C). For
these experiments, fresh stocks of these compounds were obtained from commercial sources
and dissolved in kinase buffer A. In these experiments, we found that UNC10225498 bound
PPIP5K with a Kd of 1.37 ± 0.03 μM while UNC10112646 bound PPIP5K with a Kd of
7.30 ± 0.03 μM (Fig 5). The data obtained from UNC10225354 (S5 Fig) could not be fitted to a
thermogramwith acceptable curvature for the nonlinear regression analysis required to obtain
an accurate value for Ki [48], potentially because of the compound’s poor solubility in aqueous
buffer. Moreover, UNC10225354 (also known as Doramapimod), is a potent inhibitor of p38
MAPK [44], whereas UNC10225498 and UNC10112646 are not known to interact with any
other cellular targets. Thus, the interactions of the latter two inhibitors with PPIP5K were char-
acterized in more detail.
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Investigation of the Mechanism of Inhibition of PPIP5K by
UNC10112646 and UNC20225498
To explore the mechanismwith which UNC10112646 and UNC20225498 inhibit PPIP5K, we
performed experiments with varying concentrations of ATP (Fig 6). For both inhibitors, we
found that there was an increase in the value of the IC50 when ATP concentration was increased
(Fig 6). This positive correlation indicates that both UNC10112646 and UNC20225498 compete
with ATP for the nucleotide binding site of PPIP5K (Fig 6). The Ki values for inhibition of
PPIP5K by UNC10225498 and UNC10112646 were calculated from the IC50 values determined
by the ATP competition assays using a Cheng-Prusoffmodel. The calculatedKi values for
UNC10225498 at three concentrations of ATP can be considered to be consistent (Ki[20 μM ATP]
= 1.3 μM, Ki[50 μM ATP] = 2.0 μM, Ki[100 μM ATP] = 2.6 μM) because they fall within one standard
deviation of the mean Ki value (Ki[mean] = 2.0 ± 0.6 μM). A paired t-test confirmed that these val-
ues can lie within the same normal distribution (two-tailed p value = 1.0). Likewise, the Ki values
Fig 4. Structures and dose-response relationships for three inhibitors of PPIP5Ks. Structures for (A) UNC10112646 (B) UNC10225354 and (C)
UNC10225498 (D) Dose-response curves for the inhibition of PPIP5K by UNC10225354 (IC50 = 5.24 ± 0.18 μM), UNC10225498 (IC50 = 2.14 ± 0.07 μM),
and UNC10112646 (IC50 = 6.96 ± 0.03 μM). (E) Counterscreen results for the three inhibitors performed in the absence of PPIP5K and 5-InsP7 show that
these inhibitors do not interfere with the detection reagents and assay signal. In these experiments, 100% activity is equivalent to consumption of
19.5 ± 0.8% of the ATP.
doi:10.1371/journal.pone.0164378.g004
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for UNC10112646 at the same concentrations of ATP (Ki[20 μM ATP] = 3.7 μM, Ki[50 μM ATP] =
4.9 μM, Ki[100 μM ATP] = 2.3 μM) also fall within one standard deviation of the mean Ki value
(Ki[mean] = 3.6 ± 1.3 μM) and thus can lie within the same normal distribution (two-tailed p
value = 1.0). These Ki values correlate within a factor of 2 to the Kd values determined by ITC
(Fig 5).
In silico Docking of UNC10112646 and UNC10225498 into the
Nucleotide Binding Site of PPIP5K2
To gain structural insights into PPIP5K inhibition by UNC10112646 and UNC10225498, and
to investigate the potential to improve their potencies, we performed a structural analysis of
their possible binding modes using the docking software Glide [36]. We hypothesized that
these two compounds bind to the nucleotide-binding pocket, since it represents the enzyme’s
only suitable cavity and the inhibitors acted competitively against ATP (Fig 6). There are no
previously-reported structures of PPIP5Ks with small molecules bound to the nucleotide-
Fig 5. Analysis by ITC of the interaction of UNC10225498 and UNC10112646 with PPIP5K The upper panels show the raw data for heat output
from the ligand/protein titrations; the lower panels show the least squares fitting of the titration data assuming a single site binding model. (A)
UNC10225498; Kd = 1.37 ± 0.03 μM (B) UNC10112646; Kd = 7.30 ± 0.03 μM. Representative data are shown. Kd values represent means and standard
deviations from two experiments
doi:10.1371/journal.pone.0164378.g005
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binding pocket, so for this work we used the structure of PPIP5K2 in complex with ATP (PDB:
3T54). As can be seen in Fig 7 both compounds partially overlap with ATP. In particular,
the methoxy-phenyl group of UNC10225498 (Fig 7A) and the t-butyl-phenyl group of
UNC10112646 (Fig 7B) both align with the ATP’s ribose group. However, most of the protein-
ligand interactions, mainly van derWaals contacts, occur in the entrance to the binding pocket,
by the cyanopyrimidinyl-amino-benzamide group of UNC10225498 and phenyl-imidazolyl-
piperidine group of UNC10112646. While both UNC10225498 and UNC10112646A show
hydrogen bond interactions with Lys263, UNC10225498 makes two additional hydrogen
bonds with Asp246 and Glu237 (Fig 7A). These extra proposed interactions of UNC10225498
are consistent with this being the more potent of the two inhibitors (Fig 4D).
HPLC analysis of Inhibition of Enzymatic Activity by Selected Hits
UNC10225498 and UNC10112646 emerged from our HTS screen and the ITC assays as candi-
date inhibitors of PPIP5K activity with affinities in the 1–10 μM range. We next interrogated
their efficacyusing traditional HPLC analysis to record ATP-driven conversion of 5-[3H]InsP7 to
[3H]InsP8 by PPIP5K (Fig 8A and 8B). In the control experiments (vehicle alone), 22% of the 5-
[3H]InsP7 was converted to [3H]InsP8. Upon the addition of 10 μM of either UNC10225498 or
Fig 6. Analysis of the mechanism of inhibition of PPIP5K by UNC10112646 and UNC10225498. Assays were
performed in HTS format with 2-fold serial dilutions from 100 μM of either UNC10112646 (squares) and UNC10225498
(circles) and varying concentrations of ATP as indicated. Data represent means and standard errors from 3 experiments.
The mean Ki values for inhibition of PPIP5K by UNC10225498 and UNC10112646 were 2.0 ± 0.6 μM and 3.6 ± 1.3 μM,
respectively. In these experiments, the uninhibited PPIP5K activity is equivalent to consumption of 18.9 ± 0.9% of the ATP.
doi:10.1371/journal.pone.0164378.g006
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UNC10112646, the accumulation of [3H]InsP8 was reduced by 55% (p< 0.001) and 32% (p<
0.01) respectively. These relative potencies correlate to the relative IC50 values obtained for the
inhibitors in the HTS assay (Fig 4) and their relative affinities obtained by ITC (Fig 5).
Next, we investigated the possibility that our HTS screenmight identify inhibitors of
PP-InsP synthesis that exhibit selectivity. The only other class of mammalian enzymes that
participate in PP-InsP synthesis are the IP6Ks. We recorded IP6K activity by HPLC analysis
(Fig 8C and 8D). As in the HPLC analysis of PPIP5K, we assayed IP6K using a concentration
of ATP equivalent to the enzyme’s Km value of this nucleotide.We found that neither
UNC10225498 nor UNC10112646 affectedATP-driven conversion of [3H]InsP6 to [3H]InsP7
by IP6K (p< 0.05) (Fig 8C and 8D).
Conclusions
In the current study we have designed, validated, and implemented the first HTS strategy for
any inositol phosphate kinase. The careful optimization of assay conditions and our selection
of an appropriate screening library resulted in the identification of several compounds with dif-
ferent structural scaffolds. These compounds inhibit PPIP5K activity with a potency that is an
appropriate starting point for further probe optimization (i.e., 1–10 μM) [11,49]. Molecular
modeling of two of these inhibitors in the nucleotide-binding site of PIPP5K suggest possible
core interactions. These docking poses may also aid future efforts to develop chemical probes
that may inhibit PPIP5K in intact cells in which ATP concentrations lie in the mM range.
Our data are also relevant to the subject of kinase selectivity profiling: testing for off-target
effects of a candidate kinase inhibitor against a range of other kinases. There are commercial
options for this procedure, for example, DiscoveRx’s KinomeScan array (https://www.
discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan),
which currently (July 2016) lists 490 kinases. However, while protein- and lipid-kinases are
Fig 7. The docking poses of UNC10225498 and UNC10112646 with PPIP5K. (A) UNC10225498 (thick sticks; orange carbons) (B)
UNC10112646 (thick sticks; green carbons). The ATP pocket is outlined as a gray transparent surface and ATP itself is depicted by thin magenta
sticks. Residues predicted to interact with docked compounds are highlighted (see text for details).
doi:10.1371/journal.pone.0164378.g007
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represented, inositol phosphate kinases are not. Yet in the current study we found molecules in
a protein-kinase focused library that inhibited an inositol phosphate kinase.We therefore rec-
ommend that representative inositol phosphate kinases be added to kinase selectivity profiles.
Finally, we propose that the procedures we have described in the current study may be
implemented to begin inhibitor discovery campaigns for the other inositol phosphate kinases.
Supporting Information
S1 Fig. Data fromHTS of PPIP5K in a ‘reverse’ kinase assay. A ‘reverse’ kinase assay was
performed by incubating 30 nM PPIP5K with 70 nM 1,5-InsP8 and 0.1 mMADP (i.e., its Km
Fig 8. HPLC analysis of the effects of UNC10225498 and UNC10112646 upon the kinase activities of PPIP5K and IP6K. Kinase reactions contained
either vehicle (0.5% DMSO) or inhibitor in 0.5% DMSO. Reactions were quenched and analyzed by HPLC as described in the methods section.
Representative HPLC data are shown for both (A) PPIP5K and (C) IP6K, including no enzyme control (open circles), vehicle control (closed circles), 10 μM
UNC10225498 (‘5498’, light gray circles), or UNC10112646 (‘2646’, dark gray circles). Panels B and D show the means and SEM for the percentage of
product formed in 3 experiments.
doi:10.1371/journal.pone.0164378.g008
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value) for 1 h at 25°C with individual molecules from the 5K kinase-focused library at a con-
centration of 13 μM. Next, firefly luciferase was added and we assayed the conversion of ADP
to ATP using luminescence detection. (A) The Z’ factor value (0.85 ± 0.06) obtained from 4
experiments. (B) Comparison of the mean values of biological replicates (black and white cir-
cles) measured on two different days (R2 = 0.97). Note the unmanageably high hit rate (10.2%
at >50% inhibition). Moreover, when we selected the 22 most potent hits, most of them failed
to inhibit PPIP5K in the forward assay, with the notable exception of UNC10225354 (see main
text).
(TIF)
S2 Fig. DMSO tolerance for HTS assay. PPIP5K activity was recorded in HTS format by
recording the production of ADP from ATP at the indicated concentrations of DMSO. The
ADP signal was recorded at both 0.5 h (black bars) and 4 h (gray bars) after quenching the
kinase reactions. Data represent the mean values ± SEM from three experiments.
(TIF)
S3 Fig. Structures and dose-responserelationships for inhibitors of PPIP5Ks identified
from the 5K kinase-focusedlibrary. Chemical structures and dose-response curves for the
inhibition of PPIP5K by (A) UNC10112561 (IC50 = 8.14 ± 0.05 μM), (B) UNC10112675
(IC50>13 μM), (C) UNC10225044 (IC50 = 6.84 ± 0.78 μM), (D) UNC10225045 (IC50>
13 μM), (E) UNC10225047 (IC50>13 μM), (F) UNC10225103 (IC50 = 7.37 ± 0.12 μM),
(G) UNC1025156 (IC50 = 8.18 ± 0.59 μM), (H) UNC10225159 (IC50 = 9.42 ± 0.34 μM), (I)
UNC10225183 (IC50 = 5.99 ± 0.21 μM), (J) UNC10225492 (IC50>13 μM), (K) UNC10225493
(IC50>13 μM), and (L) UNC10225499 (IC50 = 8.05 ± 0.63 μM). In these experiments, 100%
activity is equivalent to consumption of 19.5 ± 0.8% of the ATP.
(TIF)
S4 Fig. Dose-response inhibition of PPIP5K1 by UNC10225354, UNC10225498, and
UNC10112646.Dose-response curves for the inhibition of PPIP5K1 by UNC10225354 (IC50 =
2.9 ± 1.2 μM), UNC10225498 (IC50 = 1.8 ± 0.9 μM), and UNC10112646 (IC50 = 7.3 ± 0.6 μM),
Inhibition was measured using the HTRF procedures and conditions described in the Materials
and Methods. In these experiments, PIPP5K1 was used in a final concentration of 1.1 μM
and100% activity is equivalent to consumption of 18.9 ± 0.7% of the ATP.
(TIF)
S5 Fig. Analysis by ITC of the interaction of UNC10225354 with PPIP5K. The upper panel
shows the raw data for heat output from the ligand/protein titrations; the lower panel shows
the least squares fitting of the titration data assuming a single site binding model.
(TIF)
S1 Table. Clustering information for 5K library hits.Hits produced by HTS of the 5K library
fell into 10 different clusters of structural similarity.
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